Clinical trials
catalyst calendar across sponsors →Studies where TNYA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 2 observational
Held by 10 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, Squarepoint Ops LLC, +5 more) · FINRA short interest 13.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)NCT06311708observationalInvestigate the seroprevalence of pre-existing antibodies to AAV9 in patients with PKP2-associated ARVC | — | Recruiting | — | Arrhythmogenic Right Ventricular Cardiomyopathy | 200 | 2030-03-29 | in 1,318 d | 2024-11-01 |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated CardiomyopathyNCT05112237observationalTo characterize the disease course and natural history in participants with pathogenic or likely pathogenic MYBPC3 mutations with a specific focus on cardiac events and measurement | — | Recruiting | — | Cardiomyopathy | 200 | Jun 2028 | ≤ 681 d | 2024-11-13 |
| Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCMNCT05836259Number and severity of Adverse Events over the course of the study.Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Genetic: TN-201 | Hypertrophic Cardiomyopathy | 30 | Aug 2027 | ≤ 377 d | 2026-03-19 |
| Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVCNCT06228924Number and severity of Adverse Events over the course of the study.Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Genetic: TN-401 | Arrhythmogenic Right Ventricular Cardiomyopathy | 15 | 2026-05-01 | — | 2025-02-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19